New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
08:20 EDTEWEdwards Lifesciences reports positive data on Sapien 3 valve
Edwards Lifesciences announced that the first data on its most advanced commercially available transcatheter aortic heart valve, the Edwards SAPIEN 3 valve, were presented in a late-breaking clinical trial session at EuroPCR 2014 by John Webb, director of interventional cardiology and cardiac catheterization laboratories at St. Paul's Hospital, Vancouver, and professor of cardiology at the University of British Columbia. The presentation concluded that outcomes at 30 days were excellent. Transfemoral SAPIEN 3 implantation was associated with a very low mortality of 2.1%, a stroke rate of 1.0%, and very few access-site complications.
News For EW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
08:34 EDTEWEdwards Lifesciences should be bought on strong TAVR data, says Wells Fargo
Wells Fargo commends buying shares of Edwards Lifesciences after the firm viewed the most recent Transcatheter Valve Therapies registry update and estimated that the TAVR market may have grown 20% sequentially last quarter, versus its previous estimate of 1% sequential growth. The firm keeps an Outperform rating on Edwards.
07:17 EDTEWSociety of Thoracic Surgeons to hold annual meeting
51st Annual Meeting of STS is being held in San Diego, California on January 24-28.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use